A Randomized Non-inferiority Trial of Condensed Protocols for Genetic Risk Disclosure of Alzheimer ’ s Disease

Background—Conventional multi-session genetic counseling is currently recommended when disclosing APOE genotype for risk of Alzheimer’s disease (AD) in cognitively normal individuals. © 2014 The Alzheimer’s Association. All rights reserved. Corresponding author: Robert C. Green, MD, MPH, Brigham and Women’s Hospital and Harvard Medical School, EC Alumnae Building, Suite 301, 41 Avenue Louis Pasteur, Boston, MA 02115, (office) 617-264-5834, (fax) 617-264-3018, (cell) 617-966-3216, rcgreen@genetics.med.harvard.edu. *Additional members of the Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study Group are listed at the end of the manuscript None of the authors report conflicts of interest relevant to this manuscript. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. HHS Public Access Author manuscript Alzheimers Dement. Author manuscript; available in PMC 2016 June 09. Athor M anscript